ARTICLE | Clinical News
Long Acting rFactor lX: Completed Phase II/III enrollment
June 18, 2012 7:00 AM UTC
Biogen Idec said at its analyst day that it completed enrollment in the open-label, international, pivotal Phase II/III B-LONG trial evaluating a low- and high-dose regimen of IV rFIXFc in about 129 p...